SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ciphergen Biosystems(CIPH):

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (137)6/26/2003 10:00:00 PM
From: Biomaven  Read Replies (1) of 510
 
One peak significantly higher expressed in the tumor (p = 0.000029) was isolated by two-dimensional gel electrophoresis (2-DE) and identified as annexin V

Interesting. Annexin V is actually used as an agent in NASI's apomate technology. The annexin V (linked to a marker) binds to cells undergoing apoptosis (suicide) and then shows up on a scan. (I think the annexin actually binds to phosphatidylserine, which is normally found only inside a cell but reaches the surface on apoptosis). NASI is trying to use the technology to show quickly if chemotherapy is working or not.

Sounds like the sort of discovery that makes an interesting research paper, but not likely to make any money for CIPH. We're going to see hundreds (maybe thousands) of papers like this over the next few years.

Clearly CIPH have a reasonable business supplying their chips to researchers, but they obviously need much more to support their market cap. But I guess a good analogy is AFFX - they also started out supplying chips mainly to researchers, but have now moved on, at least to some extent.

I guess I'm still not absolutely sure what CIPH's business plan for the next few years looks like yet - I wonder if they have a clear idea themselves or not.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext